http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201704258-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d1ec793881a079c699607f008ee2419 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate | 2016-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6f1fc15b89b5306aa79664d6392baf3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_026d22790dfb12b646a545d1a8d4f8e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e44bf93b0602dc28f9e22f382318fb21 |
| publicationDate | 2017-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201704258-A |
| titleOfInvention | Method and polypeptide for regulating immune response |
| abstract | The present inventors have surprisingly discovered that TLT-1 binds directly to immune cells and triggers cells to express an immunosuppressive phenotype; that is, down-regulates HLA-DR and up-regulates PD-L1. Induction of PD-L1 by a polypeptide derived from TLT-1 or TLT-1 and reduction of HLA-DR can therefore be used to treat diseases associated with high immunoreactivity, such as autoimmune diseases, allergic reactions, transplant rejection and grafts. Anti-host disease. |
| priorityDate | 2015-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.